TRACON Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own TRACON Pharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
497,527
1.67%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
145,455
0.49%
0
0%
07/31/2018
Candriam Equities L - Biotechnology
143,000
0.48%
0
0.02%
07/31/2018
iShares Micro Cap ETF
48,226
0.16%
0
0.01%
09/06/2018
Russell US Small Cap Equity Fund
38,900
0.13%
18,300
0%
04/30/2018
Columbia Variable - Partners Small Cap Value Fund
36,972
0.12%
24,703
0.01%
03/31/2018
Fidelity Nasdaq Composite Index
28,234
0.1%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
25,000
0.08%
-29,135
0.01%
12/31/2017
Fidelity Spartan Extended Market Index Fund
24,629
0.08%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
18,067
0.06%
0
0%
07/31/2018
| Address |
4350 La Jolla Village Drive
San Diego California 92122
United States
|
|
Employees
|
- |
| Website |
http://www.traconpharma.com |
| Updated |
07/08/2019 |
| TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. The company products include TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, TRC205 an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. |
